AEterna Zentaris (TSX:AEZS) FCF Margin % : -4,459.88% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. AEterna Zentaris's Free Cash Flow for the three months ended in Dec. 2023 was C$-7.23 Mil. AEterna Zentaris's Revenue for the three months ended in Dec. 2023 was C$0.16 Mil. Therefore, AEterna Zentaris's FCF Margin % for the quarter that ended in Dec. 2023 was -4,459.88%.

As of today, AEterna Zentaris's current FCF Yield % is -178.05%.

The historical rank and industry rank for AEterna Zentaris's FCF Margin % or its related term are showing as below:

TSX:AEZS' s FCF Margin % Range Over the Past 10 Years
Min: -276846.15 Med: -1197.9 Max: 25.36
Current: -380.8

During the past 13 years, the highest FCF Margin % of AEterna Zentaris was 25.36%. The lowest was -276846.15%. And the median was -1197.90%.

TSX:AEZS's FCF Margin % is ranked worse than
63.06% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs TSX:AEZS: -380.80

AEterna Zentaris FCF Margin % Historical Data

The historical data trend for AEterna Zentaris's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris FCF Margin % Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-2,014.84

-113.06

-175.29

-242.74

-380.96

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-135.96	-190.93	-191.29	-114,775.00	-4,459.88

Competitive Comparison of AEterna Zentaris's FCF Margin %

For the Biotechnology subindustry, AEterna Zentaris's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's FCF Margin % distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's FCF Margin % falls into.

AEterna Zentaris FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

AEterna Zentaris's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-22.991	/	6.035
	=	-380.96 %

AEterna Zentaris's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-7.225	/	0.162
	=	-4,459.88 %

AEterna Zentaris FCF Margin % Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.